LANSOPRAZOLE EG ® is a lansoprazole-based drug.
THERAPEUTIC GROUP: Antireflux - Antiulcer-Proton pump inhibitors.
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications LANSOPRAZOL EG ® Lansoprazole
LANSOPRAZOL EG ® is indicated for the treatment of all those morbid conditions characterized by increased gastric acidity, such as duodenal and gastric ulcers, reflux esophagitis, Zollinger-Ellison syndrome, symptomatic gastroesophageal reflux disease and ulcers associated with prolonged therapy with anti-inflammatory drugs non-steroidal drugs.
This medicine, in combination with an antibiotic is also useful in the eradicating treatment of Helicobacter Pylori.
Mode of action LANSOPRAZOLO EG ® Lansoprazole
Lansoprazole, contained in LANSOPRAZOL EG ® is another active ingredient belonging to the family of proton pump inhibitors.
Its therapeutic action is due to the ability to selectively inhibit the H + / K + ATPase pump expressed by the parietal cells of the stomach, involved in the acid secretion of the intragastric lumen, which results in a reduction of the acid content of the stomach by about 80% in basal conditions than under stimulation.
The medicine reaches its maximum effectiveness after about 7 days, when the inhibiting capacity reaches values even higher than 80%.
Compared to its predecessors such as omeprazole, lansoprazole is improved from the pharmacokinetic point of view, reaching a bioavailability of about 80/90% of the total dose taken, with a maximum plasma peak that is observed within 120 minutes of intake.
Following a hepatic metabolism, more precisely hydroxylation and sulfation, supported in part by the cytochrome p450 isoforms CYP2C19 and CYP3A4, its metabolites are eliminated mainly through the urine.
Studies carried out and clinical efficacy
1. BMI, GASTROESOFAGEO REFLUX AND INHIBITORS OF THE PROTONIC PUMP
In many patients without H.Pylori infections or high pathologies, there is an impaired functionality of the lower esophageal sphincter, involved in the genesis of gastroesophageal reflux disease. In these patients it was noted that the body mass index was not only associated with the greater incidence of reflux but also with the different therapeutic response to proton pump inhibitors, thus becoming important as a predictor of the development of the pathology and of the possible therapeutic efficacy.
2. LANSOPRAZOLE AND STOMACH BURNERS
Heartburn is one of the most frequent symptoms in the western population, and not always associated with a specific pathology. Among the different therapeutic treatments, the one with 15 mg of lansoprazole daily for 14 weeks, seems to be the most effective and best tolerated, guaranteeing a prompt and lasting response.
3. A NEW THERAPEUTIC APPROACH TO GASTRITIS
Gastritis is an inflammation of the gastric mucosa, often characterized by a progressive course, and not always related to a clear etiological connection. New therapeutic approaches have shown that the concomitant administration of lansoprazole and selective COX2 inhibitors can significantly improve gastritis, modulating lymphocyte activation.
Method of use and dosage
LANSOPRAZOLE EG ® 15 -30 mg gastro-resistant hard capsules of lansoprazole:
the most used dosage in clinical practice is 30 mg daily, preferably taken in the morning with a glass of water.
The therapeutic action should be completed within 4 weeks, even if, under strict medical indication, and in case of failure to achieve the therapeutic goals, therapy could be extended up to 8 weeks.
Different, lower dosages in the treatment of gastroesophageal reflux, higher in the treatment of Zollinger-Ellison syndrome, should be evaluated during therapy.
Any adaptation of the dosage used should be decided by the competent doctor, after a careful evaluation of the patient's physiopathological conditions.
Warnings LANSOPRAZOLE EG ® Lansoprazole
Before taking LANSOPRAZOLO EG ® it would be appropriate to ascertain the origin of gastro-intestinal diseases, so that therapy with lansoprazole does not mask signs and symptoms important for a correct diagnosis, thus delaying the therapeutic intervention.
Given the hepatic metabolism and renal secretion of this active ingredient, it should be taken with particular care, and under strict medical supervision in patients with reduced kidney and liver function.
It is also important to remember that prolonged administration of antacids and proton pump inhibitors may expose the patient to the risk of Salmonella and Campylobacter infections.
The presence of sucrose in the medicine, could determine the appearance of diseases of the gastro-intestinal tract in patients suffering from reduced tolerance to fructose, glucose / galactose or maltase, isomaltase and saccharase enzyme deficiency.
The appearance of drowsiness, headache, dizziness and dizziness could determine a reduction in the patient's perceptive capacities, making it dangerous to use machinery and drive vehicles.
PREGNANCY AND BREASTFEEDING
The absence of clinical trials and experimental studies showing the effects of lansoprazole, when taken during pregnancy, on the health of the unborn child and of the pregnant woman, do not allow to establish the safety profile of the drug. Therefore the use of LANSOPRAZOL EG ® is contraindicated also in pregnancy and in the subsequent period of breastfeeding, given the possibility that the active ingredient is secreted in breast milk.
Interactions
The metabolism of lansoprazole, supported by highly reactive cytochrome p450 isoforms, exposes this drug to a high number of possible interactions with other active ingredients metabolized by the same system.
More precisely, drugs such as ketoconazole, itraconazole, protease inhibitors, macrolides and fluvoxamine can cause a significant increase in lansoprazole concentrations, increasing the risk of unpleasant side effects.
On the contrary, lansoprazole could determine an alteration of the pharmacokinetic properties of farfari, phenytoin and theophylline.
Concomitant intake of antacids and sucralfate could instead reduce the bioavailability of lansoprazole.
Contraindications LANSOPRAZOLE EG ® Lansoprazole
Given the presence of cross-reactivity LANSOPRAZOL EG ® is contraindicated in case of hypersensitivity to the active substance or to other proton pump inhibitors.
Undesirable effects - Side effects
LANSOPRAZOL EG ® therapy has proved to be quite safe and well tolerated, with common side effects such as nausea, diarrhea, stomach pain, flatulence and dyspepsia, eczema, urticaria, pruritus, asthenia, headache, drowsiness and dizziness.
Clinically more relevant side reactions, with alterations in liver, renal, endocrine and neurological function have been observed rarely and especially in particular categories of patients at risk.
In any case the symptomatology tends to spontaneous regression once the therapy is suspended.
Note
LANSOPRAZOLO EG ® is salable only under medical prescription.
